1. Copyright © 2013 Quintiles
The Collaboration
Mandate
July 2013
Adam Istas
Thought Leadership Director - Quintiles

2. 2
The Collaboration Mandate
• Objectives
> Since 2010 Quintiles has commissioned
independent research to develop and publish
The New Health Report.
• Methodology
> 53 Provider executives
- Representing integrated healthcare systems and
academic medical centers
- 100% from the US
> 143 Payer executives
- 68 from managed care organizations in the US
- 75 from government payer organizations in Europe
» (France, Germany, Italy, Spain, United Kingdom)
> 102 Biopharmaceutical executives
- Vice-president level and above
- At least 25% from outside the U.S.
Objectives & Methodology
102
68
75
53
Biopharma
US Payers
EU Payers
Providers

3. 3
The Collaboration Mandate
Key Findings
Payers, providers and
biopharma agree that
they need to be better
aligned with other
stakeholders in the
healthcare industry, yet
they have struggled to
achieve this goal.
Only 16-19% of survey
respondents said they
were mostly aligned
with other
stakeholders, while
one-fourth said they
are not very or not at
all aligned.

4. 4
The Collaboration Mandate
Key Findings
All three groups rated
improved health
outcomes and
innovation among the
greatest benefits of
cross-stakeholder
initiatives.
Payers are also
interested in reducing
the cost of
care, providers seek
improved care
experiences and
biopharma wants to
accelerate the rate at
which new therapies
get to market.

5. 5
The Collaboration Mandate
Key Findings
More than 70% of all
stakeholders believe
transparency around
data sources and
information-sharing
across stakeholders is
very important or
critically important to
the success of an
interoperable
healthcare system.
Their biggest obstacles
to adopting a systems-
oriented approach are
lack of trust, poor
financial incentives and
varying definitions of
value.

6. 6
The Collaboration Mandate
Key Findings
At least three out of
four survey participants
believe it is very
important or extremely
important for data
sources collected by
different stakeholders
to be linked together to
better inform decisions.
However, more than
half feel they have
neither the tools nor
the expertise to
optimize use of these
data sets.

7. 7
Implications / Recommendations
The report outlines recommendations for biopharma to improve their
collaboration to benefit business and improve patient outcomes.
• Diversify partnerships to drive innovation. Seek opportunities to partner with
stakeholders from across the healthcare continuum. Ideally these opportunities will
stretch comfort zones beyond the traditional regulatory partnerships, with the promise
of innovation in exchange for transparency and a willingness to work collaboratively for
mutual benefit.
• Build the roadmap together. Define success and then work in concert with partners
to build the roadmap to get there. When collaboration has a destination, every
individual heads in the same direction.
• Foster—and use—feedback. Regularly review results through formal check points
and feedback channels with a focus on how to continually optimize design based on
system feedback. Ensure stakeholders stay connected to the team and foster a culture
of trust by communicating results and feedback regularly across the stakeholder
community.

8. 8
Contact Information
Mari Mansfield, Corporate Communications
mari.mansfield@quintiles.com
O: +1 919 998 2639
M: +1 919 259 3298
Laura Wilson, Corporate Communications - Europe
laura.e.wilson@quintiles.com
O: +44 118 450 8392
M: +44 7854 173 106
> http://www.quintiles.com/collaborationmandate
For additional information about The Collaboration Mandate